Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cyclin D protein inhibitor polypeptide and application thereof

A technology of protein inhibitors and injections, which is applied in the field of polypeptides for the treatment of mantle cell lymphoma, can solve problems that have not yet been developed, and achieve the effect of increasing survival rate and inhibiting tumor growth

Active Publication Date: 2014-09-03
SHENZHEN HUAZHONG BIOLOGICAL PHARMA MACHINERY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no drug for the treatment of mantle cell lymphoma that has developed a mature Cyclin D protein inhibitor polypeptide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyclin D protein inhibitor polypeptide and application thereof
  • Cyclin D protein inhibitor polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Effect of Cyclin D protein inhibitor peptide 1 on migration of Mino in human mantle cell lymphoma cells.

[0019] Using scratch test. First use a marker pen on the back of the 24-well plate, and use a ruler to draw horizontal lines evenly, about every 0.5~1cm, across the holes. Three lines were passed through each well; Mino cells growing in pairs were added to a 24-well culture plate at a density of 1.0×105, and cultured for 24 hours. On the second day, compare the ruler with a 10 μl pipette tip, scratch perpendicular to the horizontal line on the back, and use the intersection of the scratch and the horizontal line on the back as a fixed observation point; add different concentrations of experimental wells and positive drug control wells respectively. The drug Cyclin D protein inhibitor polypeptide 1 and the positive control drug vincristine; the same volume of solvent was added to the blank group, and five replicate holes were set in each well; 2 Incubator, culture...

Embodiment 2

[0023] Effect of Cyclin D protein inhibitor peptide 1 on the proliferation of human mantle cell lymphoma cells Mino.

[0024] The MTT assay was used to detect the activity of the peptides in inhibiting the growth of Mino cells. Mino cells at 37°C, 5% CO 2 When the incubator was cultivated to a confluence of more than 90%, it was digested with trypsin and collected, and the cells were resuspended in the culture medium and counted under the microscope, and the cell concentration was adjusted to 2×10 4 cells / ml, inoculate the cell suspension into 96-well plate, 100 μl / well, and incubate at 37°C, 5% CO 2 Incubate overnight in the incubator. The polypeptides are diluted with culture medium to each predetermined concentration. Endostar was diluted with culture medium to the final concentration. After the cells were completely adhered to the wall, each dilution was added to a 96-well plate (100 μl / well). Adding the integrin blocking agent polypeptide dilution was used as the adm...

Embodiment 3

[0031] Inhibition of Cyclin D protein inhibitor polypeptide 1 on human mantle cell lymphoma cell Mino xenograft tumor growth in nude mice

[0032] Take the human mantle cell lymphoma Mino cell line in the logarithmic growth phase, and prepare 5 × 10 cells under sterile conditions. 7 / ml cell suspension, inoculated subcutaneously in the right armpit of nude mice with 0.1ml. Use a vernier caliper to measure the diameter of the transplanted tumor in nude mice, and wait until the tumor grows to 100-200mm 3 Animals were then randomly grouped. Using the method of measuring tumor diameter, dynamically observe the anti-tumor effect of the tested polypeptide. Tumor diameter was measured every 2 days. The method of administration was by tail vein injection. The negative control group was injected with the same amount of normal saline once a day; the paclitaxel group was given 10 mg / kg once a week; the endostar group was given 2.5 mg / kg once a day; 10mg / kg, 5mg / kg, administered once...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicaments, and in particular relates to polypeptide with functions of inhibiting Cyclin D protein expression and treating mantle cell lymphoma, the sequence is ETIRRAYPDAANLLNDRVL which is a brand-new sequence, the polypeptide is capable of in vitro inhibiting Mino cell proliferation and migration of the mantle cell lymphoma cell and treating the mantle cell lymphoma; the survival rate of mice is successfully increased in a body bearing cancer model experiment, and the potential new medicine development value is provided.

Description

technical field [0001] The present invention relates to Cyclin D protein inhibitor polypeptide 1 and its application, in particular to a polypeptide capable of inhibiting Cyclin D protein expression and treating mantle cell lymphoma. Background technique [0002] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin's lymphoma characterized by overexpression of t(11;14)(q13;q32) and cyclin D1. It is a moderately malignant lymphoma with long-term survival The rate is very low. It is common in the elderly, mostly in men, with a median age of 60 years. MCL is prone to relapse and is the lymphoma subtype with the lowest long-term survival rate, with a median survival period of 3 to 5 years. The clinical manifestations are aggressive, the disease progresses rapidly, and there are usually extensive lymph node involvement, extranodal lesions are common, liver, spleen, peripheral blood and bone marrow are often infiltrated, often accompanied by multiple gastrointestinal involvement a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/08A61K38/10A61P35/00
Inventor 罗瑞雪
Owner SHENZHEN HUAZHONG BIOLOGICAL PHARMA MACHINERY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com